LỌC MÁU HẤP PHỤ BẰNG MÀNG LỌC OXIRIS® CHO BỆNH NHÂN COVID-19: TỔNG QUAN HỆ THỐNG VÀ PHÂN TÍCH ĐỊNH TÍNH

Abstract

Objective: To synthesize and qualitatively analyze current clinical evidence on the efficacy of oXiris hemoadsorptipn in patients with severe COVID-19, focusing on its impact on physiological parameters and clinical outcomes. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines. Comprehensive research was performed in PubMed, Embase, Web of Science, and Scopus for studies published from 2020 to June 2025. Eligible studies involved oXiris hemoadsorptipn and reported at least one of the following outcomes: mortality, PaO₂/FiO₂ (P/F) ratio, Sequential Organ Failure Assessment (SOFA) score, interleukin-6 (IL-6) levels, or vasopressor requirements. Given the heterogeneity in study designs and outcomes, a narrative synthesis was conducted. Results: Twenty-eight studies were included: 3 randomized controlled trials, 7 controlled observational studies, and the remainder being case series or observational reports. These studies encompassed 341 patients in the oXiris group and 253 in control groups. Many reported improvements in P/F ratio, reductions in IL-6 levels, and decreases in SOFA scores following hemoadsorptipn. However, findings regarding mortality and vasopressor use were inconsistent. Conclusion: oXiris hemoadsorptipn may provide physiological and clinical benefits for patients with severe COVID-19. However, the current evidence is limited by small sample sizes, non-comparative study designs, and methodological variability. Larger, well-designed randomized controlled trials are needed to clarify their true efficacy and safety in this context.